×
Zura Bio Price/Book Ratio 2022-2024 | ZURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Zura Bio price/book ratio from 2022 to 2024. Price/book ratio can be defined as
View More
Zura Bio Price/Book Ratio 2022-2024 | ZURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Zura Bio price/book ratio from 2022 to 2024. Price/book ratio can be defined as
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$152.1B
Vertex Pharmaceuticals (VRTX)
$120.6B
Bristol Myers Squibb (BMY)
$120.1B
Gilead Sciences (GILD)
$115.4B
CSL (CSLLY)
$89B
Regeneron Pharmaceuticals (REGN)
$82.4B
GSK (GSK)
$70.7B
Argenex SE (ARGX)
$37.2B
Alnylam Pharmaceuticals (ALNY)
$32.6B
BioNTech SE (BNTX)
$28.4B
Biogen (BIIB)
$23.4B
Illumina (ILMN)
$22.9B
BeiGene (BGNE)
$20.9B
Moderna (MRNA)
$16.6B
Incyte (INCY)
$14.4B
Genmab (GMAB)
$14.2B
Insmed (INSM)
$13.4B
Sarepta Therapeutics (SRPT)
$12.7B
BioMarin Pharmaceutical (BMRN)
$12.6B
Bio-Techne Corp (TECH)
$12B
Vaxcyte (PCVX)
$11.8B
Exact Sciences (EXAS)
$11.5B
Exelixis (EXEL)
$10.4B
QIAGEN (QGEN)
$9.9B
Revolution Medicines (RVMD)
$9.7B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$9.3B
Intra-Cellular Therapies (ITCI)
$9.1B
Repligen (RGEN)
$8.4B
Ascendis Pharma (ASND)
$8.3B